Bear,

Yes Pfizer came to the party for the ZEN-3694 and PARP inhibitor as a trial collaboration only,   But Pfizer has very little  real skin in the game other than sharing clinical costs , no real risk to them,   All the R & D over the past 6 years have all been paid by Zenith to this point.  I would like to see a real partnership deal with large upfront money and then a CVR deal for a buyout if all works out on the mCRPC trial if the data from the trial is really good.    Pfizer Came to party and maybe a little dance but know marriage yet....we'll see what happens